Key result
CD147 contributes to SARS-CoV-2-triggered progressive pulmonary fibrosis by promoting fibroblast activation, and treatment with the CD147 antibody meplazumab alleviates this fibrotic progression in mice.
Why the study?
Does targeting CD147 with meplazumab or genetic knockout prevent SARS-CoV-2-induced pulmonary fibrosis in mouse models?
Does targeting CD147 with meplazumab or genetic knockout prevent SARS-CoV-2-induced pulmonary fibrosis in mouse models?
CD147 is a crucial regulator of fibroblast activation in SARS-CoV-2 infection, and its targeted inhibition with meplazumab represents a potential therapeutic strategy for post-COVID-19 pulmonary fibrosis.
Answers are grounded in this paper and cite their sources.
Meplazumab may warrant human trials for post-COVID fibrosis; leaves open translation from mouse models to clinical practice.
COVID-19 patients can develop clinical and histopathological features associated with fibrosis, but the pathogenesis of fibrosis remains poorly understood. CD147 has been identified as a universal receptor for SARS-CoV-2 and its variants, which could initiate COVID-19-related cytokine storm. Here, we systemically analyzed lung pathogenesis in SARS-CoV-2- and its delta variant-infected humanized CD147 transgenic mice. Histopathology and Transmission Electron Microscopy revealed inflammation, fibroblast expansion and pronounced fibrotic remodeling in SARS-CoV-2-infected lungs. Consistently, RNA-sequencing identified a set of fibrosis signature genes. Furthermore, we identified CD147 as a crucial regulator for fibroblast activation induced by SARS-CoV-2. We found conditional knockout of CD147 in fibroblast suppressed activation of fibroblasts, decreasing susceptibility to bleomycin-induced pulmonary fibrosis. Meplazumab, a CD147 antibody, was able to inhibit the accumulation of activated fibroblasts and the production of ECM proteins, thus alleviating the progression of pulmonary fibrosis caused by SARS-CoV-2. In conclusion, we demonstrated that CD147 contributed to SARS-CoV-2-triggered progressive pulmonary fibrosis and identified CD147 as a potential therapeutic target for treating patients with post-COVID-19 pulmonary fibrosis.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2022) studied SARS-CoV-2-induced pulmonary fibrosis. Meplazumab (CD147 antibody) and CD147 knockout vs. IgG control or wild-type was evaluated on Pulmonary fibrosis progression (fibroblast activation and ECM protein production). CD147 contributes to SARS-CoV-2-triggered progressive pulmonary fibrosis by promoting fibroblast activation, and treatment with the CD147 antibody meplazumab alleviates this fibrotic progression in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: